Cancer Prevention Clinical Trials Network
Gastrointestinal and Other Cancers
National Cancer Institute (NCI)
For more information, see ClinicalTrials.gov NCT04550481
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced liver function. Lisinopril is a medication that is commonly used to treat high blood pressure. Lisinopril may help to decrease liver fibrosis. The purpose of this trial is to find out what effect, if any, lisinopril has on a patient's risk of developing liver cancer.
Lisinopril, Questionnaire Administration, Biospecimen Collection, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Ju Dong Yang, Douglas T. Dieterich, Manal F. Abdelmalek, Cynthia A. Moylan